Spots Global Cancer Trial Database for stage i multiple myeloma
Every month we try and update this database with for stage i multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00482495 | Multiple Myelom... | bevacizumab gene expression... protein express... laboratory biom... | 18 Years - | Mayo Clinic | |
| Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00006890 | Multiple Myelom... | prednisone thalidomide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | NCT00024466 | Multiple Myelom... | GVAX Autologous tran... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma | NCT00005987 | Multiple Myelom... | carmustine cyclophosphamid... dexamethasone etoposide filgrastim mitoxantrone hy... recombinant int... sargramostim bone marrow abl... peripheral bloo... radiation thera... | - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Interleukin-12 in Treating Patients With Multiple Myeloma | NCT00003149 | Multiple Myelom... | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00075881 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | NCT00064038 | Multiple Myelom... Plasma Cell Neo... | dexamethasone lenalidomide placebo | 18 Years - | SWOG Cancer Research Network | |
| Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00729118 | Multiple Myelom... Plasma Cell Neo... | lenalidomide vorinostat | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide | NCT00899080 | Multiple Myelom... | gene expression... reverse transcr... immunoenzyme te... laboratory biom... platelet aggreg... | - 120 Years | Eastern Cooperative Oncology Group | |
| S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00040937 | Multiple Myelom... | filgrastim sargramostim cyclophosphamid... dexamethasone melphalan prednisone thalidomide peripheral bloo... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00075881 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004165 | Multiple Myelom... | filgrastim melphalan peripheral bloo... | - | Northwestern University | |
| Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00478075 | Multiple Myelom... | bortezomib immunologic tec... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | NCT00400686 | Anemia Multiple Myelom... Plasma Cell Neo... | epoetin alfa | 18 Years - | The Cleveland Clinic | |
| Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00742404 | Multiple Myelom... | bortezomib dexamethasone pegylated lipos... protein analysi... immunologic tec... | 18 Years - | National Cancer Institute (NCI) | |
| Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | NCT00006244 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | melphalan recombinant int... aldesleukin in vitro-treate... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment | NCT00389701 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Beta Alethine in Treating Patients With Myeloma | NCT00006466 | Multiple Myelom... Precancerous Co... | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT01074060 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim cyclophosphamid... autologous hema... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | NCT00005834 | Multiple Myelom... | filgrastim cisplatin cyclophosphamid... dexamethasone etoposide thalidomide | 18 Years - | SWOG Cancer Research Network | |
| Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00568880 | Multiple Myelom... | bortezomib hydroxychloroqu... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | NCT00064038 | Multiple Myelom... Plasma Cell Neo... | dexamethasone lenalidomide placebo | 18 Years - | SWOG Cancer Research Network | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | NCT00334932 | Multiple Myelom... | bortezomib melphalan pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | NCT00998049 | Multiple Myelom... Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim | 18 Years - | Mayo Clinic | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | NCT00743288 | Multiple Myelom... | Melphalan Panobinostat | 18 Years - | Oncotherapeutics | |
| Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00008229 | Multiple Myelom... | filgrastim melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma | NCT00004088 | Multiple Myelom... | filgrastim recombinant int... busulfan cyclophosphamid... melphalan pamidronate dis... thalidomide peripheral bloo... | - 65 Years | City of Hope Medical Center | |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | NCT00112879 | Stage I Multipl... Stage II Multip... Stage III Multi... Refractory Plas... | arsenic trioxid... ascorbic acid dexamethasone thalidomide anti-cytokine t... antiangiogenesi... biological ther... chemotherapy drug resistance... growth factor a... non-specific im... | 18 Years - | National Cancer Institute (NCI) | |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | NCT00064038 | Multiple Myelom... Plasma Cell Neo... | dexamethasone lenalidomide placebo | 18 Years - | SWOG Cancer Research Network | |
| Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | NCT00002556 | Stage I Multipl... Stage II Multip... Stage III Multi... | vincristine sul... carmustine melphalan cyclophosphamid... prednisone recombinant int... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00045136 | Multiple Myelom... | melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma | NCT00499577 | Multiple Myelom... | CMV pp65 peptid... hTERT I540/R572... pneumococcal po... survivin Sur1M2... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00477750 | Multiple Myelom... | lenalidomide melphalan prednisone | 18 Years - | Mayo Clinic | |
| High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | NCT01534143 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | pharmacological... tacrolimus sirolimus anti-thymocyte ... fludarabine pho... busulfan bortezomib allogeneic hema... laboratory biom... | 18 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00941720 | Multiple Myelom... | busulfan cyclophosphamid... autologous hema... | 18 Years - | Case Comprehensive Cancer Center | |
| Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients | NCT01653106 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | cryotherapy questionnaire a... pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | NCT00522392 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | NCT00998049 | Multiple Myelom... Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim | 18 Years - | Mayo Clinic | |
| Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00941720 | Multiple Myelom... | busulfan cyclophosphamid... autologous hema... | 18 Years - | Case Comprehensive Cancer Center | |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01055301 | Multiple Myelom... Plasma Cell Mye... | bortezomib cisplatin cyclophosphamid... dexamethasone doxorubicin hyd... etoposide lenalidomide melphalan thalidomide gene expression... microarray anal... laboratory biom... autologous-auto... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain | NCT00482378 | Multiple Myelom... Pain | Pamidronate Zoledronic acid Sm 153 lexidron... | 18 Years - 120 Years | Mayo Clinic | |
| Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | NCT01057225 | Multiple Myelom... Stage I Multipl... Stage II Multip... Stage III Multi... | carfilzomib cyclophosphamid... thalidomide dexamethasone | 18 Years - | Mayo Clinic | |
| Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure | NCT00416897 | Multiple Myelom... Renal Failure | chemotherapy dexamethasone plasmapheresis | 18 Years - | National Cancer Institute (NCI) | |
| O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma | NCT00004072 | Multiple Myelom... | O6-benzylguanin... carmustine | - | Case Comprehensive Cancer Center | |
| Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | NCT00602706 | Multiple Myelom... | sargramostim melphalan autologous hema... peripheral bloo... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00477750 | Multiple Myelom... | lenalidomide melphalan prednisone | 18 Years - | Mayo Clinic | |
| Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00008229 | Multiple Myelom... | filgrastim melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00028600 | Multiple Myelom... Plasma Cell Neo... | filgrastim CD34+ cells cyclophosphamid... fludarabine pho... melphalan methotrexate tacrolimus | - 64 Years | Alliance for Clinical Trials in Oncology | |
| Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant | NCT01706666 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib cyclophosphamid... lenalidomide laboratory biom... dexamethasone quality-of-life... | 18 Years - | Mayo Clinic | |
| Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma | NCT00049673 | Multiple Myelom... | prednisone thalidomide | 16 Years - | Canadian Cancer Trials Group | |
| Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004158 | Multiple Myelom... | melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00075881 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01055301 | Multiple Myelom... Plasma Cell Mye... | bortezomib cisplatin cyclophosphamid... dexamethasone doxorubicin hyd... etoposide lenalidomide melphalan thalidomide gene expression... microarray anal... laboratory biom... autologous-auto... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma | NCT00897910 | Multiple Myelom... | flow cytometry immunoenzyme te... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00017602 | Multiple Myelom... | oblimersen sodi... dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma | NCT00432458 | Multiple Myelom... | Thalidomide zoledronic acid | 18 Years - | Mayo Clinic | |
| Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant | NCT00469820 | Leukemia Multiple Myelom... | autologous tumo... peripheral bloo... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia | NCT00004181 | Chronic Myelopr... Leukemia Multiple Myelom... | busulfan cyclophosphamid... allogeneic bone... radiation thera... | 15 Years - 55 Years | Northwestern University | |
| Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant | NCT00288028 | Multiple Myelom... | bortezomib | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment | NCT00389701 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00719901 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | obatoclax mesyl... bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma | NCT00432458 | Multiple Myelom... | Thalidomide zoledronic acid | 18 Years - | Mayo Clinic | |
| Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma | NCT00317798 | Drug/Agent Toxi... Multiple Myelom... | anti-thymocyte ... sirolimus | 18 Years - | University of Rochester | |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | NCT00400686 | Anemia Multiple Myelom... Plasma Cell Neo... | epoetin alfa | 18 Years - | The Cleveland Clinic | |
| Combination Chemotherapy in Treating Patients With Multiple Myeloma | NCT00002678 | Multiple Myelom... | dexamethasone melphalan prednisone | 18 Years - 120 Years | Canadian Cancer Trials Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
